Puma Biotechnology
PBYI
92 hedge funds and large institutions have $1.22B invested in Puma Biotechnology in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 32 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
21% more capital invested
Capital invested by funds: $1.01B → $1.22B (+$212M)
10% more funds holding
Funds holding: 84 → 92 (+8)
9% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 32
0.07% more ownership
Funds ownership: 79.12% → 79.19% (+0.07%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$78.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$17.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.3M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$8.72M |
| 5 |
SCM
Sigma Capital Management
Stamford,
Connecticut
|
+$5.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$22.2M |
| 2 |
JP Morgan Chase
New York
|
-$14.6M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$14.2M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$13.6M |
| 5 |
O
OrbiMed
New York
|
-$13.1M |
PBYI Hedge Fund Activity: Q3 2013 in Review
92 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2013, worth a combined $1.22B — up 21% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PBYI positions and 9 closed out — a net gain of 9 holders — while 35 added to existing stakes and 32 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $78.8M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $22.2M.
- 92 institutional investors held Puma Biotechnology (PBYI) as of Q3 2013, up from 84 in Q2 2013.
- Funds reported $1.22B of Puma Biotechnology stock for Q3 2013, up 21% quarter-over-quarter.
- 18 funds opened new Puma Biotechnology positions in Q3 2013 and 9 closed out, a net change of +9 holders.
- The largest Puma Biotechnology buyer in Q3 2013 was Lord, Abbett & Co, an estimated $78.8M added.
- The largest Puma Biotechnology seller in Q3 2013 was Bain Capital Public Equity Management, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2013.